Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency

NCT00978380 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00978380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00978380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
September 21, 2009
Completion date
October 20, 2015
Enrollment
63 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, congenital fxiii deficiency